You just read:

SurgiMab Recruits First US Patient in Pivotal Phase 3 Trial Evaluating SGM-101, a Novel Fluorescent Tumor-specific Antibody, for the Improvement of Surgical Outcomes in Colorectal Cancer Patients

News provided by

SurgiMab

Oct 17, 2019, 05:30 ET